Fundamental to the authors’ findings is the important demonstration of the safety
of using newer anticoagulants in early postop cardiac surgical patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Seminars in Thoracic and Cardiovascular SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- New-onset atrial fibrillation after coronary artery bypass graft and long-term risk of stroke: A meta-analysis.J Am Heart Assoc. 2017; 6https://doi.org/10.1161/JAHA.117.007558
- Perioperative atrial fibrillation and the long-term risk of ischemic stroke.JAMA. 2014; 312: 616-622https://doi.org/10.1001/jama.2014.9143
- Non-Vitamin K antagonist oral anticoagulant vs warfarin for post cardiac surgery atrial fibrillation.Ann Thorac Surg. 2021; 0https://doi.org/10.1016/j.athoracsur.2020.12.031
- Andexanet alfa for the reversal of Factor Xa Inhibitor activity.N Engl J Med. 2015; 373: 2413-2424https://doi.org/10.1056/NEJMoa1510991
- Idarucizumab for dabigatran reversal—Full cohort analysis.N Engl J Med. 2017; 377: 431-441https://doi.org/10.1056/NEJMoa1707278
- Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365: 981-992https://doi.org/10.1056/NEJMoa1107039
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365: 883-891https://doi.org/10.1056/NEJMoa1009638
- Safety of direct oral anticoagulants compared to warfarin for atrial fibrillation after cardiac surgery: A systemic review and meta-analysis.Semin Thorac Cardiovasc Surg. 2022; 34: 947-957
- Rationale and design of the randomized controlled trial of new oral anticoagulants vs. warfarin for post cardiac surgery atrial fibrillation: The NEW-AF Trial.Ann Surg. 2020; (Publish Ahead of Print:440-453)https://doi.org/10.1097/sla.0000000000004459
Article info
Publication history
Published online: June 14, 2021
Footnotes
Conflicts of Interest: Neither author has a conflict of interest with respect to the content of this Commentary and the publication for which it is being submitted.
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Safety of Direct Oral Anticoagulants Compared to Warfarin for Atrial Fibrillation after Cardiac Surgery: A Systematic Review and Meta-AnalysisSeminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
- PreviewThe evidence for use of direct oral anticoagulants (DOACs) in the management of post-operative cardiac surgery atrial fibrillation is limited and mostly founded on clinical trials that excluded this patient population. We performed a systematic review and meta-analysis of clinical trials and observational studies to evaluate the hypothesis that DOACs are safe compared to warfarin for the anticoagulation of patients with post-operative cardiac surgery atrial fibrillation. We searched PubMed, EMBASE, Web of Science, clinicaltrials.gov, and the Cochrane Library for clinical trials and observational studies comparing DOAC with warfarin in patients ≥18 years old who had post-cardiac surgery atrial fibrillation.
- Full-Text
- Preview
